CardioFocus initiates clinical evaluation of HeartLight endoscopic ablation system

The company has initiated a clinical evaluation of its HeartLight X3 endoscopic ablation system for treating atrial fibrillation (AF).

Medical device maker CardioFocus (Marlborough, MA) has initiated a clinical evaluation of the company's HeartLight X3 endoscopic ablation system for treating atrial fibrillation (AF).

Related: CardioFocus to accelerate market expansion of HeartLight endoscopic ablation system

Building upon the advanced features of the current HeartLight system—direct tissue visualization, titratable laser energy, and compliant balloon technology—HeartLight X3 is designed to deliver rapid, continuous, 360° lesions as a pulmonary vein isolation (PVI) tool for AF. Its RAPID mode of operation leverages a precise motor control system that enables uninterrupted, high-speed lesion creation.

The initial cases were completed at Na Homolce Hospital (Prague, Czech Republic) and performed by Petr Neužil, MD, Ph.D., Head of the Department of Cardiology, and his team.

The clinical evaluation of the HeartLight X3 System is planned to continue throughout 2018, with regulatory submissions to occur thereafter.

For more information, please visit www.cardiofocus.com.

More in Biophotonics Tools